Holen Sie sich die Stockscreener-App
74.53
0.79%
-0.15
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Barclays PLC Buys 33,494 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration - Sahm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Yahoo Finance UK
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Performance Recap: What is Apogee Therapeutics Incs 5 year growth outlookJuly 2025 Pullbacks & Accurate Buy Signal Alerts - baoquankhu1.vn
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Vanguard Group Inc. Has $89.22 Million Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (APGE) Gets a Buy from Mizuho Securities - The Globe and Mail
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - MarketBeat
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
Apogee’s Deeper Losses and New Shelf Filing Test Its High-Risk Pipeline Strategy (APGE) - simplywall.st
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com South Africa
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating - marketscreener.com
APOGEE THERAPEUTICS ($APGE) Releases Q4 2025 Earnings - Quiver Quantitative
Apogee Therapeutics (NASDAQ:APGE) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
APGE: Strong pipeline progress and robust cash reserves position for key data and trial milestones in 2026 - TradingView
Apogee Therapeutics 2025 10-K: $0 Revenue; EPS $(4.22) - TradingView
Apogee Therapeutics (NASDAQ: APGE) advances long-acting AD biologics - Stock Titan
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results - GlobeNewswire
Precision Trading with Apogee Therapeutics Inc. (APGE) Risk Zones - Stock Traders Daily
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
A Look At Apogee Therapeutics (APGE) Valuation As Great Point Partners Lifts Its Stake - simplywall.st
JPMorgan Chase & Co. Purchases 417,161 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
APGE SEC FilingsApogee Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - The Motley Fool
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Promising Biotech with Nearly 50% Upside Potential - DirectorsTalk Interviews
Apogee Therapeutics to Participate in Upcoming March Conferences - The Manila Times
Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday - Defense World
Aberdeen Group plc Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - MSN
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is Apogee Therapeutics Inc. s 5 year growth outlookJuly 2025 Rallies & Stock Market Timing Techniques - mfd.ru
End of Apogee (APGE) drug collaboration leads to revised analyst expectations - MSN
Apogee Therapeutics Rings the Closing Bell - Nasdaq
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations - Finviz
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):